stockrow
Friday 6 November 2026
Export AEON’s income statement to Excel — free account
AEON Biopharma, Inc.
AEON Healthcare Biotechnology
- EPS
- +96.7%
- Free cash flow
- −76.9%
- Total debt
- −88.4%
Quarter to June 2026, against a year earlier
0.18
0.02
+12.50%
Follow AEON
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 22 | +582.6% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | 0 | 8 | (53) | (385) | 42 | (39) | (55) | +541.9% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | 0 | 8 | (53) | (385) | 42 | (39) | (55) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (0.04) | 86.67 | (27.23) | (745.41) | 77.74 | (3.95) | (4.42) | +153.9% | ||||||
| Cash flow | — | — | — | — | 0.00 | (15.80) | (18.44) | (92.68) | (37.58) | (1.74) | (0.27) | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | (15.80) | (18.60) | (92.68) | (37.58) | (1.74) | (0.27) | n/m | ||||||
| Book value | — | — | — | — | 0.26 | (178.96) | (140.11) | (296.60) | (52.91) | (5.55) | (0.30) | n/m | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 2 | 1 | 1 | 10 | 28 | +160.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (36) | (48) | (20) | (17) | (14) | +84.5% | |||||
| Capex | — | — | — | — | — | — | 0 | — | — | 0 | 0 | (76.4%) | ||||||
| Free cash flow | — | — | — | — | — | (1) | (36) | (48) | (20) | (17) | (14) | +84.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 0 | (73) | (7) | (13) | (3) | (3) | +143.5% | |||||
| Net debt | — | — | — | — | 0 | 0 | 122 | (5) | 12 | 32 | (3) | +336.7% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | (17) | (270) | (153) | (29) | (55) | (15) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (8.89) | 5.92 | (36.53) | (4,365.11) | 841.19 | (901.45) | (621.70) | (892.6) pt | |||||
| ROIC | — | — | — | — | (5.45) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +5.5 pt | ||||||
| ROE | — | — | — | — | 0.00 | (97.00) | 36.58 | 181.66 | (46.26) | 93.84 | 350.00 | +93.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 3 | 10 | 5 | 8 | — | +27.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
AEON Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LPCN Lipocine Inc. | $12.6M | — (loss-making) | — (loss-making) | +1,898.32% (above 0%: growing) | n/m | +39.46% (above 0%: growing) | 100.00% | (37.93%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $12.3M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| DARE Dare Bioscience, Inc. | $12.3M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| GUTS Fractyl Health, Inc. | $11.9M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| HIND Vyome Holdings, Inc. | $11.4M | — (loss-making) | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| CLRB Cellectar Biosciences, Inc. | $10.9M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AEON AEON Biopharma, Inc. | $9.4M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | |
| Median of peers | $12.1M | — | — | −46.00% | — | −23.86% | 51.14% | (92.80%) |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
9.40%
Entities affiliated with Daewoong Co., LTD.
49.90%
Entities affiliated with Pointilist Partners LLC
9.90%
Entities affiliated with Dauntless Investment Group, LLC
9.90%
Wukuan Jia
8.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement